Featuring Dov S. Zakheim, Senior Advisor, Center for Strategic and International Studies; Mackenzie Eaglen, Resident Fellow at the Marilyn Ware Center for Security Studies, American Enterprise Institute; Todd Harrison, Senior Fellow, Defense Budget Studies, Center for Strategic and Budgetary Assessments; and Christopher A. Preble, Vice President for Defense and Foreign Policy Studies, Cato Institute; moderated by Kate Brannen, Senior Reporter, Foreign Policy.
In the new issue of Regulation, economist Pierre Lemieux argues that the recent oil price decline is at least partly the result of increased supply from the extraction of shale oil. The increased supply allows the economy to produce more goods, which benefits some people, if not all of them. Thus, contrary to some commentary in the press, cheaper oil prices cannot harm the economy as a whole.
Two long wars, chronic deficits, the financial crisis, the costly drug war, the growth of executive power under Presidents Bush and Obama, and the revelations about NSA abuses, have given rise to a growing libertarian movement in our country – with a greater focus on individual liberty and less government power. David Boaz’s newly released The Libertarian Mind is a comprehensive guide to the history, philosophy, and growth of the libertarian movement, with incisive analyses of today’s most pressing issues and policies.
Featuring Donald Abrams, M.D., Director of Clinical Programs, Osher Center for Integrative Medicine, University of California; Robert DuPont, M.D., President, Institute for Behavior and Health; Rob Kampia, Executive Director, Marijuana Policy Project; Moderated by Tim Lynch, Director, Project on Criminal Justice, Cato Institute
Ten years ago, on March 17, 1999, an important government study was released regarding certain patients’ use of marijuana as prescribed by their doctors. The Institute of Medicine, a branch of the National Academy of Sciences, issued what was then the most comprehensive analysis of the scientific and medical literature about marijuana. The report stated, “The accumulated data indicate a potential therapeutic value for cannabinoid drugs, particularly for symptoms such as pain relief, control of nausea and vomiting, and appetite stimulation.”Many medical experts continue to caution about harms that may result from smoking marijuana, though those harms need to be weighed against other harms that particular patients may be facing. In the political realm, the debate over the legal status of medical marijuana continues to rage. Since 1996, 12 states have legalized marijuana for medical use. What have medical scientists learned about marijuana over the past 10 years? And how have the politics on this contentious issue shifted at the federal and state level? Join us for a lively discussion of the science and politics of medical marijuana.